203 related articles for article (PubMed ID: 2436247)
1. Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease.
Sunderland T; Tariot PN; Cohen RM; Newhouse PA; Mellow AM; Mueller EA; Murphy DL
Psychopharmacology (Berl); 1987; 91(3):293-6. PubMed ID: 2436247
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of clorgyline on catecholamine and indoleamine metabolites in the cerebrospinal fluid of rhesus monkeys.
Garrick NA; Scheinin M; Chang WH; Linnoila M; Murphy DL
Biochem Pharmacol; 1984 May; 33(9):1423-7. PubMed ID: 6203542
[TBL] [Abstract][Full Text] [Related]
3. The effects of amiflamine on cerebrospinal fluid amine metabolites in the rhesus monkey.
Garrick NA; Seppala T; Linnoila M; Murphy DL
Eur J Pharmacol; 1985 Mar; 110(1):1-9. PubMed ID: 2408906
[TBL] [Abstract][Full Text] [Related]
4. Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer type. Influence of treatment with L-deprenyl.
Martignoni E; Bono G; Blandini F; Sinforiani E; Merlo P; Nappi G
J Neural Transm Park Dis Dement Sect; 1991; 3(1):15-25. PubMed ID: 1712206
[TBL] [Abstract][Full Text] [Related]
5. N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl.
Karoum F
Br J Pharmacol; 1987 Feb; 90(2):335-45. PubMed ID: 3103805
[TBL] [Abstract][Full Text] [Related]
6. [Concentrations of monoamines and monoamine metabolites in cerebrospinal fluid determined by high-performance liquid chromatography with electrochemical detection].
Yoshino K
No To Shinkei; 1982 Nov; 34(11):1099-106. PubMed ID: 6186264
[TBL] [Abstract][Full Text] [Related]
7. Tyramine pressor sensitivity changes during deprenyl treatment.
Sunderland T; Mueller EA; Cohen RM; Jimerson DC; Pickar D; Murphy DL
Psychopharmacology (Berl); 1985; 86(4):432-7. PubMed ID: 3929314
[TBL] [Abstract][Full Text] [Related]
8. Phenylethylamine and monoamine metabolites in CSF of schizophrenics: effects of neuroleptic treatment.
Beckmann H; Waldmeier P; Lauber J; Gattaz WF
J Neural Transm; 1983; 57(1-2):103-10. PubMed ID: 6194254
[TBL] [Abstract][Full Text] [Related]
9. Rhesus monkey cerebrospinal fluid amine metabolite changes following treatment with the reversible monoamine oxidase type-A inhibitor cimoxatone.
Garrick NA; Seppala T; Linnoila M; Murphy DL
Psychopharmacology (Berl); 1985; 86(3):265-9. PubMed ID: 2412251
[TBL] [Abstract][Full Text] [Related]
10. Monoamine metabolite concentrations in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia.
Palmer AM; Sims NR; Bowen DM; Neary D; Palo J; Wikstrom J; Davison AN
J Neurol Neurosurg Psychiatry; 1984 May; 47(5):481-4. PubMed ID: 6204017
[TBL] [Abstract][Full Text] [Related]
11. Correlated reductions in cerebrospinal fluid 5-HIAA and MHPG concentrations after treatment with selective serotonin reuptake inhibitors.
Sheline Y; Bardgett ME; Csernansky JG
J Clin Psychopharmacol; 1997 Feb; 17(1):11-4. PubMed ID: 9004051
[TBL] [Abstract][Full Text] [Related]
12. Monoamines and their metabolites in cerebrospinal fluid of patients with senile dementia of Alzheimer type using high performance liquid chromatography and gas chromatography-mass spectrometry.
Parnetti L; Gottfries J; Karlsson I; Långström G; Gottfries CG; Svennerholm L
Acta Psychiatr Scand; 1987 May; 75(5):542-8. PubMed ID: 2440238
[TBL] [Abstract][Full Text] [Related]
13. CSF monoamine metabolite levels in Alzheimer's and Parkinson's disease.
Gibson CJ; Logue M; Growdon JH
Arch Neurol; 1985 May; 42(5):489-92. PubMed ID: 2581531
[TBL] [Abstract][Full Text] [Related]
14. Repetitive measurement of monoamine metabolite levels in cerebrospinal fluid of conscious rats: effects of reserpine and haloperidol.
Scheinin H; Scheinin M
Eur J Pharmacol; 1985 Jul; 113(3):345-51. PubMed ID: 2412847
[TBL] [Abstract][Full Text] [Related]
15. Monoamine metabolite levels in rat CSF: kinetic studies.
Scheinin H; Scheinin M
Pharmacol Toxicol; 1987 Sep; 61(3):167-71. PubMed ID: 2446306
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid monoamine metabolites and neuropeptides in patients with panic disorder.
Lepola U; Jolkkonen J; Pitkänen A; Riekkinen P; Rimón R
Ann Med; 1990; 22(4):237-9. PubMed ID: 1701091
[TBL] [Abstract][Full Text] [Related]
17. Monoamine metabolites in human cerebrospinal fluid: indicators of neuronal activity?
Scheinin M
Med Biol; 1985; 63(1):1-17. PubMed ID: 2582215
[TBL] [Abstract][Full Text] [Related]
18. Concentrations of monoamine metabolites in the cerebrospinal fluid of twins and unrelated individuals--a genetic study.
Oxenstierna G; Edman G; Iselius L; Oreland L; Ross SB; Sedvall G
J Psychiatr Res; 1986; 20(1):19-29. PubMed ID: 2423688
[TBL] [Abstract][Full Text] [Related]
19. Monoamine metabolites in cerebrospinal fluid and behavioral ratings in patients with early and late onset of Alzheimer dementia.
Bråne G; Gottfries CG; Blennow K; Karlsson I; Lekman A; Parnetti L; Svennerholm L; Wallin A
Alzheimer Dis Assoc Disord; 1989; 3(3):148-56. PubMed ID: 2477044
[TBL] [Abstract][Full Text] [Related]
20. CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression.
Molchan SE; Lawlor BA; Hill JL; Martinez RA; Davis CL; Mellow AM; Rubinow DR; Sunderland T
Biol Psychiatry; 1991 Jun; 29(11):1110-8. PubMed ID: 1714776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
